Genes encoding proteins involved in dopaminergic transmission have been of special interest during the evaluation of candidate genes for Parkinson's disease (PD). The dopamine D2 receptor gene (DRD2) is located on chromosome 11 q22-q23, and several polymorphisms of the gene have been described. The
Association of the DRD2 and DRD3 polymorphisms with response to pramipexole in Parkinson’s disease patients
✍ Scribed by Ying-Zi Liu; Bei-Sha Tang; Xin-Xiang Yan; Jie Liu; Dong-Sheng Ouyang; Li-Nuo Nie; Lan Fan; Zhi Li; Wei Ji; Dong-Li Hu; Dan Wang; Hong-Hao Zhou
- Publisher
- Springer
- Year
- 2009
- Tongue
- English
- Weight
- 101 KB
- Volume
- 65
- Category
- Article
- ISSN
- 0031-6970
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract Previous studies have demonstrated that the __TaqIA__ polymorphism of the D2 dopamine receptor gene (__DRD__2) is associated with response to dopaminergic and antidopaminergic treatment in Parkinson's disease (PD) and schizophrenia, respectively. We tested whether the __TaqIA__ genotype
## Abstract We aimed to assess whether allelic variants of dopamine receptor, glutamate receptor, and serotonin transporter genes are associated with the appearance of impulse control and related behaviors (ICRB) in Parkinson's disease (PD) with dopamine replacement therapy (DRT). We surveyed ICRB
## Abstract It is hypothesized that molecular components of dopaminergic system, especially the dopamine D3 receptor gene (DRD3), may play a crucial role in the pathophysiology of schizophrenia, because it is abundant in the limbic system of the brain and it binds antipsychotic drugs. Several group
## Abstract In addition to levodopa treatment and disease duration, genetic predisposition might contribute to the development of medication‐related complications in Parkinson's disease (PD). As recent observations indicate the dopamine D~3~ receptor (DRD3) to modulate both therapeutic action of le